Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy.

about

Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy.

Item

http://www.wikidata.org/entity/Q47144269

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Chimerism in Myeloid Malignanc ...... Pharmacokinetics versus BuCy.

@en

Chimerism in Myeloid Malignanc ...... Pharmacokinetics versus BuCy.

@nl

type

Item

label

Chimerism in Myeloid Malignanc ...... Pharmacokinetics versus BuCy.

@en

Chimerism in Myeloid Malignanc ...... Pharmacokinetics versus BuCy.

@nl

prefLabel

Chimerism in Myeloid Malignanc ...... Pharmacokinetics versus BuCy.

@en

Chimerism in Myeloid Malignanc ...... Pharmacokinetics versus BuCy.

@nl

P1476

Chimerism in Myeloid Malignanc ...... Pharmacokinetics versus BuCy.

@en

P2093

Edward Peres

http://www.w3.org/2001/XMLSchema#string

Klodiana Neme

http://www.w3.org/2001/XMLSchema#string

Michael Bazydlo

http://www.w3.org/2001/XMLSchema#string

Nalini Janakiraman

http://www.w3.org/2001/XMLSchema#string

Nancy Mikulandric

http://www.w3.org/2001/XMLSchema#string

P2860

Plasma concentration monitoring of busulfan: does it improve clinical outcome?

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

Lack of utility of chimerism studies obtained 2-3 months after myeloablative hematopoietic cell transplantation for ALL.

Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival

Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and mu

Therapeutic drug monitoring of busulfan in transplantation.

Relapse after allogeneic stem cell transplantation

Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia.

P304

8690416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2017/8690416

http://www.w3.org/2001/XMLSchema#string

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

Shatha Farhan

P577

2017-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29250116

http://www.w3.org/2001/XMLSchema#string

P932

5698787

http://www.w3.org/2001/XMLSchema#string